Advertisement
Canada markets close in 4 hours 18 minutes

  • S&P/TSX

    21,993.14
    +121.18 (+0.55%)
     

  • S&P 500

    5,061.47
    +50.87 (+1.02%)
     

  • DOW

    38,427.22
    +187.24 (+0.49%)
     

  • CAD/USD

    0.7314
    +0.0013 (+0.17%)
     

  • CRUDE OIL

    82.62
    +0.72 (+0.88%)
     

  • Bitcoin CAD

    91,064.91
    +704.37 (+0.78%)
     

  • CMC Crypto 200

    1,435.97
    +21.21 (+1.50%)
     

  • GOLD FUTURES

    2,335.20
    -11.20 (-0.48%)
     

  • RUSSELL 2000

    2,003.46
    +35.99 (+1.83%)
     

  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     

  • NASDAQ

    15,674.46
    +223.16 (+1.44%)
     

  • VOLATILITY

    16.27
    -0.67 (-3.96%)
     

  • FTSE

    8,044.48
    +20.61 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6832
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?

Zacks Equity Research

Epizyme Inc. EPZM is expected to release fourth-quarter 2019 results on Feb 24.

The company’s surprise history has been impressive so far. Its earnings beat estimates in the trailing four quarters by 20.94%, on average. In the third quarter, Epizyme reported a positive earnings surprise of 25.93%.

Shares of Epizyme have surged 106.1% in the past year against the industry’s decline of 1.9%.

Let’s see how things are shaping up for the quarter to be reported.

Key Developments in Q4

In January 2020, the FDA granted accelerated approval to lead drug, tazemetostat, for the treatment of adults and pediatric patients aged 16 years or above with metastatic or locally advanced epithelioid sarcoma (ES) not eligible for complete resection. The drug will be marketed under the brand name, Tazverik. We expect the company to provide commercialization updates on the drug during the fourth-quarter earnings call.

ADVERTISEMENT

The company is also working on expanding the label of Tazverik and submitted another new drug application to the FDA for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. The same was accepted by the FDA in February 2020 with an action date of Jun 18, 2020.

In January 2020, Epizyme announced that it exercised its option to sell $50 million of its common stock to Royalty Pharma. Epizyme expects that this additional capital combined with the existing cash, cash equivalents and marketable securities will further support its current operating runway into 2022, which includes the planned launch of tazemetostat for ES and FL indications. We expect the company to provide an update on the same along with fourth-quarter results.

The company is likely to have incurred higher operating expenses related to commercialization activities and other clinical developments for Tazverik during the to-be-reported quarter.

Why a Likely Earnings Beat

Our proven model predicts an earnings beat for Epizyme this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Earnings ESP: Epizyme has an Earnings ESP of +3.92%, as the Zacks Consensus Estimate stands at a loss of 51 cents and the Most Accurate Estimate is pegged at a loss of 49 cents.

Zacks Rank: The company carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.

 

Epizyme, Inc. Price and EPS Surprise

 

Epizyme, Inc. Price and EPS Surprise
Epizyme, Inc. Price and EPS Surprise

Epizyme, Inc. price-eps-surprise | Epizyme, Inc. Quote

Other Stocks That Warrant a Look

Here are a few other healthcare stocks worth considering, as our model shows that these too have the right mix of elements to beat estimates this time around.

Vericel Corporation VCEL has an Earnings ESP of +11.29% and a Zacks Rank #1. The company is scheduled to release fourth-quarter results on Feb 25.

AMAG Pharmaceuticals, Inc. AMAG has an Earnings ESP of +31.03% and a Zacks Rank #3.

Sage Therapeutics Inc. SAGE has an Earnings ESP of +2.74% and a Zacks Rank #3. The company is scheduled to release fourth-quarter results on Feb 27.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMAG Pharmaceuticals, Inc. (AMAG) : Free Stock Analysis Report
 
Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report
 
Epizyme, Inc. (EPZM) : Free Stock Analysis Report
 
Vericel Corporation (VCEL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research